-
Mashup Score: 20Unanswered questions following reports of secondary malignancies after CAR-T cell therapy - 4 month(s) ago
Nature Medicine – Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Unanswered questions following reports of secondary malignancies after CAR-T cell therapy - 4 month(s) ago
Nature Medicine – Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Unanswered questions following reports of secondary malignancies after CAR-T cell therapy - 4 month(s) ago
Nature Medicine – Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Unanswered questions following reports of secondary malignancies after CAR-T cell therapy - 4 month(s) ago
Nature Medicine – Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Unanswered questions following reports of secondary malignancies after CAR-T cell therapy - 4 month(s) ago
Nature Medicine – Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
Joint #ASTCT/#ISCT/#EBMT/#CIBMTR statement - https://t.co/otOakndIqp bottom line - the benefit of #CARTcells likely exceed the potential low (probably very low) risk of T-cell malignancies after CAR-T @DrMiguelPerales